Pharma's Almanac TV
PA TV
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2021 Cell & Gene Therapy Report
2021 Monoclonal Antibody & Recombinant Protein Market Report
2021 Sterile Drug Market Report
2021 API Market Report
2020 OSD Market Report
Community
Company A to Z
More+
Staffing
Media Kit
COVID-19
235 Articles Available
1
10
Can't find what you're looking for? Try our
advanced search
.
COVID-19 Nasal Spray
ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose
PR-M07-21-05
COVID-19 Vaccine
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
PR-M06-21-028
COVID-19 Testing
Roche Obtains CE Mark for the SARS-CoV-2 Antigen Self Test Nasal Allowing for Rapid Self Testing of COVID-19 At Home
PR-M06-21-027
Partnership
Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™
PR-M06-21-024
COVID-19
Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities
PR-M06-21-020
Genetic Vaccines
Working to Overcome Analytical Challenges Posed by Genetic Vaccines
PAO-06-21-NI-01
COVID-19 Treatment
Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for Ensovibep for the Treatment of COVID-19
PR-M06-21-003
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine
PR-M05-21-016
Vaccines
A Look at Genetic Vaccine Development and Manufacturing
PAO-05-21-NI-03
COVID-19 Vaccines
The COVID-19 Vaccine Journey Continues
PAO-05-21-NI-02
Emergency Use
Pfizer and BioNtech Receive First U.S. Authorization for Emergency Use of Covid-19 Vaccine in Adolescents
PR-M05-21-007
COVID-19 Vaccine
iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program
PR-M05-21-005
Immunity
The Link Between COVID-19 and Immunity
PTV-04-21-CL-003
COVID-19 Diagnostic
FDA Authorizes First Single-Use, PCR Quality Over the Counter (OTC) LUCIRA CHECK IT™ COVID-19 At-Home Test. Available Now.
PR-M04-21-016
COVID
Regeneron Phase III Trial Shows 81% Reduced Risk of COVID
PR-M04-21-014
COVID-19
Lilly Modified COVID-19 Purchase Agreement for Bamlanivimab and Etesevimab Together
PR-M04-21-010
Vaccine
Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
PR-M04-21-006
Clinical Trials
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data From the Phase 2 Blaze-4 Trial Evaluating Bamlanivimab With Vir-7831 in Low-risk Adults With Covid-19
PR-M04-21-004
Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV
PR-M03-21-006
Endpoints
NeuroRx Announces ZYESAMI™ Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
PR-M03-21-005
COVID-19 Impacts
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
PAO-03-21-NI-01
COVID-19 Therapeutics
Tevogen Bio Announces Partnership With BioCentriq to Enhance Tevogen’s Development Capacity of Its Proprietary Targeted T Cell Therapy For COVID-19
PR-M03-21-002
COVID-19 Vaccine
UBC Announces Initiative to Accelerate COVID-19 Vaccine Real-World Evidence Generation
PR-M11-20-046
COVID-19 Vaccine
HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine
PR-M11-20-031
1
10
»
